Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

H Beltran; L Fazli; CC Collins; JA Eastham; MJ Morris; ME Taplin; A Sboner; S Halabi; ME Gleave; AW Wyatt; E Chedgy; A Donoghue; M Annala; E Warner; K Beja; M Sigouros; F Mo

doi:10.1158/1078-0432.CCR-17-1034

Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

H Beltran, L Fazli, CC Collins, JA Eastham, MJ Morris, ME Taplin, A Sboner, S Halabi, ME Gleave, AW Wyatt, E Chedgy, A Donoghue, M Annala, E Warner, K Beja, M Sigouros, F Mo

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

66 Sitaatiot (Scopus)

Alkuperäiskieli	Englanti
Sivut	6802-6811
Julkaisu	Clinical Cancer Research
Vuosikerta	23
Numero	22
DOI - pysyväislinkit	https://doi.org/10.1158/1078-0432.CCR-17-1034
Tila	Julkaistu - 2017
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Julkaisufoorumi-taso

Jufo-taso 2

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

Pääsy asiakirjaan

10.1158/1078-0432.CCR-17-1034

Siteeraa tätä

Beltran, H., Fazli, L., Collins, CC., Eastham, JA., Morris, MJ., Taplin, ME., Sboner, A., Halabi, S., Gleave, ME., Wyatt, AW., Chedgy, E., Donoghue, A., Annala, M., Warner, E., Beja, K., Sigouros, M., & Mo, F. (2017). Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy. Clinical Cancer Research, 23(22), 6802-6811. https://doi.org/10.1158/1078-0432.CCR-17-1034

@article{aa0da12365e84d73a3a96f191898b991,

title = "Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy",

author = "H Beltran and L Fazli and CC Collins and JA Eastham and MJ Morris and ME Taplin and A Sboner and S Halabi and ME Gleave and AW Wyatt and E Chedgy and A Donoghue and M Annala and E Warner and K Beja and M Sigouros and F Mo",

year = "2017",

doi = "10.1158/1078-0432.CCR-17-1034",

language = "English",

volume = "23",

pages = "6802--6811",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

number = "22",

}

Beltran, H, Fazli, L, Collins, CC, Eastham, JA, Morris, MJ, Taplin, ME, Sboner, A, Halabi, S, Gleave, ME, Wyatt, AW, Chedgy, E, Donoghue, A, Annala, M, Warner, E, Beja, K, Sigouros, M & Mo, F 2017, 'Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy', Clinical Cancer Research, Vuosikerta 23, Nro 22, Sivut 6802-6811. https://doi.org/10.1158/1078-0432.CCR-17-1034

TY - JOUR

T1 - Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

AU - Beltran, H

AU - Fazli, L

AU - Collins, CC

AU - Eastham, JA

AU - Morris, MJ

AU - Taplin, ME

AU - Sboner, A

AU - Halabi, S

AU - Gleave, ME

AU - Wyatt, AW

AU - Chedgy, E

AU - Donoghue, A

AU - Annala, M

AU - Warner, E

AU - Beja, K

AU - Sigouros, M

AU - Mo, F

PY - 2017

Y1 - 2017

U2 - 10.1158/1078-0432.CCR-17-1034

DO - 10.1158/1078-0432.CCR-17-1034

M3 - Article

SN - 1078-0432

VL - 23

SP - 6802

EP - 6811

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 22

ER -